🇺🇸

Earnings Results

· daily

US Earnings Financial Results SEC Filings — June 01, 2026

The 16 filings for the period ending June 1, 2026, reveal a deeply bifurcated market. While a few large-cap names like Agilent Technologies and SAIC delivered strong earnings growth and shareholder returns, the majority of filers, particularly small-cap and pre-revenue companies, are in severe distress. A dominant theme is the cash burn crisis among micro-cap firms: Idaho Copper, Rapid Line, Electronic Servitor Publication Network, and NaturalShrimp are all reporting widening losses, zero or declining revenue, and deteriorating liquidity, with several carrying going-concern warnings. The insurance and tobacco sectors show specific stress, with Freedom Holding Corp.'s insurance revenue dropping 30% and Universal Corp. taking a $41.1M goodwill impairment. On the positive side, Agilent posted a standout 10% revenue growth with a 57.7% net income surge, and SAIC's aggressive buybacks are significantly boosting EPS. The overall picture is one of a 'haves and have-nots' market, where capital is flowing to quality while speculative and cash-negative entities face existential threats.

16 high priority 16 total filings
· daily

US Earnings Financial Results SEC Filings — May 29, 2026

The 32 filings reveal a bifurcated market where large-cap tech and select industrials (HEICO, Autodesk, MongoDB) are delivering robust growth and margin expansion, while consumer-facing and small-cap names (Target, Toll Brothers, FingerMotion, Stemtech) face significant headwinds. Revenue growth is a key differentiator: Snowflake (+33.5% YoY), MongoDB (+25.3%), and Autodesk (+18.4%) lead, contrasting with declines at FingerMotion (-32%), Stemtech (-43%), and Norris Industries (-13%). Margin trends are equally divergent, with TJX and Gap showing strong operating leverage, while Target and Toll Brothers suffer from cost inflation and impairment charges. Insider activity is sparse but notable, with no major buying or selling patterns detected. Capital allocation is aggressive at the top end, with Walmart, Copart, and Gap executing large buybacks, while distressed micro-caps like Nutra Pharma and Stemtech are issuing shares for debt settlement. The most critical development is the divergence in consumer health: Walmart's 7.3% revenue growth signals strength in value retail, while Target's 22.9% operating income decline and Toll Brothers' 26.1% net income drop suggest pressure on discretionary and higher-end spending. The portfolio-level pattern is a 'flight to quality' favoring companies with recurring revenue, strong free cash flow, and pricing power.

32 high priority 32 total filings
· daily

US Earnings Financial Results SEC Filings — May 28, 2026

The 33 filings reveal a mixed earnings season with revenue growth across most companies but notable margin compression and rising costs. Key themes include strong performance in AI-related and infrastructure services (Marvell, Dycom, EPLUS), while consumer-facing companies (BJ's, Hormel) face margin pressure. Several SPACs and micro-caps show severe cash burn (Aerkomm, IWAC). Insider activity is limited, but capital allocation trends show aggressive buybacks at Salesforce and HealthEquity. Forward-looking data is sparse, but upcoming earnings calls for Deere and Lowe's are key catalysts. Overall, growth is broad but profitability is challenged by restructuring, acquisition costs, and rising SG&A.

33 high priority 33 total filings
· daily

US Earnings Financial Results SEC Filings — May 27, 2026

The 41 filings reveal a bifurcated earnings season. While top-line growth is present across several sectors (Home Depot +4.8%, Box +10.7%, AMSC +34.3%, Synopsys +41.9%), margin compression and rising costs are a dominant theme, with 5 of 16 new filings showing operating income declines despite revenue growth. The most acute distress is concentrated in micro-cap companies like Hi-Great Group (revenue -46.6%, cash near zero) and Nature's Miracle (revenue -96%), while larger firms like Modine and U-Haul face operational headwinds from depreciation and restructuring charges. Insider activity is notably absent from the enriched data, but capital allocation patterns show aggressive buybacks at Box ($115M in quarter) and Synopsys ($262.5M), contrasted with dividend increases at StepStone (+37% YoY). The 25 CarMax trust filings are procedural and carry no actionable intelligence. The most compelling opportunities lie in AMSC's 34% revenue growth with a swing to profitability, Semtech's 37% net income growth, and nCino's operational leverage (swung from -$1.5M to +$21.1M operating income).

41 high priority 41 total filings
· daily

US Earnings Financial Results SEC Filings — May 26, 2026

Financial results for the period show a mixed landscape: some companies achieved strong revenue growth (CSW Industrials +23%, Zscaler +25%, Digital Turbine +15%, OpGen +481%), but margin compression and widening losses are common themes. Five of thirteen filers reported net losses worsening year-over-year, with Kailera Therapeutics and Apimeds Pharmaceuticals seeing losses surge due to R&D and digital asset impairments, respectively. Cash positions are deteriorating across several small-cap names (T-REX, ConnectM, Hubilu), while Digital Turbine and Hubilu showed improved cash flow. No insider trading activity was reported in any filing. Forward-looking guidance was absent, but capital allocation trends indicate reinvestment in growth (Zscaler R&D +37%, Kailera R&D +602%) and debt management (Digital Turbine interest expense +68%). Sector disparities are evident: tech/software firms sustain growth with losses, healthcare/biotech face high cash burn, and industrials see margin pressure amid revenue gains.

13 high priority 13 total filings
· daily

US Earnings Financial Results SEC Filings — May 22, 2026

The 30 filings reveal a bifurcated market: high-growth companies like Trutankless (+347% YoY revenue) and Reborn Coffee (+208% YoY) show explosive top-line expansion but face severe cash burn and liquidity risks, while established firms like CorVel (+7% revenue, +16% net income) and Workday (+13.5% revenue) demonstrate steady growth with improving margins. A notable theme is the prevalence of SPACs and pre-revenue companies (Pyrophyte, Thunder Power, Two Hands) reporting widening losses and cash depletion, with 5 of 30 filings showing zero revenue. Insider activity is sparse but includes significant share repurchases at Williams-Sonoma ($287.8M) and Workday ($1.6B), signaling management confidence. Capital allocation trends favor buybacks over dividends, with 4 companies aggressively repurchasing shares. The office REIT sector (OPIRQ) remains distressed, with three consecutive quarterly losses and Chapter 11 restructuring. Overall, the data suggests investors should favor companies with positive operating cash flow and sustainable growth, while avoiding cash-burning entities with going-concern risks.

30 high priority 30 total filings
· daily

US Earnings Financial Results SEC Filings — May 21, 2026

The 22 filings reveal a bifurcated market: consumer-facing and tech companies (e.g., e.l.f. Beauty, Logitech, Ralph Lauren) show robust top-line growth, but margin pressures from rising costs and acquisition-related charges are compressing net income. Conversely, the semiconductor and industrial sectors (Applied Materials, Allegro MicroSystems, Nordson) demonstrate strong cyclical recoveries with double-digit revenue and earnings growth. A critical undercurrent is acute liquidity stress at micro-cap companies (Dalrada, Apple iSports, Barnwell), where cash burn and negative equity signal potential distress. Capital allocation is a key differentiator: strong operators like Cirrus Logic and Hamilton Lane are returning capital via buybacks, while others (Advanced Drainage Systems, Thermon) are absorbing restructuring costs. Insider trading data is sparse, but the lack of insider buying at struggling firms is a notable negative signal. The overarching theme is that quality and scale are rewarded, while smaller, cash-poor entities face existential risks.

22 high priority 22 total filings
· daily

US Earnings Financial Results SEC Filings — May 20, 2026

The 50 filings reveal a bifurcated market: growth companies like Analog Devices (+37% YoY revenue) and AEVEX Corp (swinging to $21M net income from a $27M loss) are thriving, while a broad swath of micro-cap and pre-revenue firms face severe liquidity crises, with 15+ companies reporting widening net losses and cash burn. Period-over-period trends show revenue growth concentrated in industrial, defense, and niche tech, while consumer-facing and energy-exposed firms struggle. Insider activity is sparse, but management teams at distressed companies are issuing dilutive securities at alarming rates. Capital allocation is defensive—debt reduction and equity raises dominate, with only a few firms (e.g., Immunovant) strengthening balance sheets via offerings. The most critical development is the wave of going-concern warnings and negative equity positions across 10+ filings, signaling potential bankruptcies. Portfolio-level patterns include margin compression in manufacturing (EnerSys -100 bps gross margin) and a surge in impairment charges (Heritage Distilling $62.1M, Haemonetics $86.5M).

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 19, 2026

The 36 filings from May 19, 2026, reveal a bifurcated market where top-line growth is often masking underlying margin compression and cash flow deterioration. A clear theme is 'growth at a cost,' with companies like Cisco (12% revenue growth) and Energy Vault (156% revenue growth) showing strong sales but facing margin pressure or widening losses. Conversely, several micro-cap and pre-revenue companies (e.g., ShorePower, RMX Industries) are experiencing severe revenue declines and cash burn, signaling distress. Insider activity is notably absent from the filings, limiting conviction signals, but capital allocation patterns show a mix of aggressive reinvestment (Eagle Materials, Movano) and debt-fueled growth (Nextpower, James Hardie). The most actionable intelligence lies in identifying companies with genuine operational leverage versus those masking structural issues with one-time gains or accounting adjustments. Key sectors to watch include energy storage (Energy Vault's explosive growth vs. cash burn) and building materials (James Hardie's AZEK integration vs. Eagle Materials' margin resilience).

36 high priority 36 total filings
· daily

US Earnings Financial Results SEC Filings — May 18, 2026

The 27 filings reveal a stark bifurcation in the US micro-cap landscape: revenue growth is concentrated in a few outliers (CBAK Energy +99%, Hyperscale Data + Bally's Corp + Catheter Precision), while the majority of filers show revenue declines, zero revenue, or zero revenue with zero revenue. Period-over-period data shows aggregate revenue for the 27 filers fell ~15% YoY, with 14 of 27 reporting lower or zero revenue. Margin compression is severe—CBAK Energy's gross profit collapsed 78% despite revenue doubling, and NanoVibronix swung to a gross loss. Insider activity is absent in most filings, but capital allocation signals distress: 8 companies have zero cash, 5 are funding operations solely via related-party loans, and dilution is rampant (NanoVibronix shares outstanding surged 236% in one quarter). Forward-looking data is sparse, but scheduled events (earnings calls) for Bally's Corp and Hyperscale Data offer near-term catalysts. The most actionable themes are the 'cash-zero' cohort (6 companies with zero cash) and the 'revenue growth vs. margin destruction' trade-off in CBAK Energy and Hyperscale Data.

27 high priority 27 total filings
· daily

US Earnings Financial Results SEC Filings — May 14, 2026

Across 50 Q1 2026 10-Q filings, overarching themes include mixed sentiment dominated by SPACs (e.g., Inflection Point, SUMA, Sizzle) generating net income from trust interest (avg ~$1-2M per quarter) amid operating losses and cash burn, while operating companies show polarized revenue trends: 12/25 reported YoY growth (avg +70%, led by Healthcare Triangle +166%, BitGo +113%) but 13 saw declines (avg -40%, e.g., New Fortress -52%, Swarmer -82%). Margin compression affected 8/15 detailed cos (avg -150 bps) due to rising opex/R&D, though gross margins expanded in winners like Enovix (+495% gross profit). Balance sheets bolstered by financings/IPOs (e.g., Cabaletta cash +41% QoQ, Swarmer +153%), but cash burn intensified in 20+ cos (avg op cash use $1-3M). Capital allocation leans conservative with distributions up in REITs/BDCs (Blue Owl +7%, Oaktree Gardens +30% YoY), few buybacks. No widespread insider activity reported, but high materiality names (New Fortress 9/10, StubHub 9/10) signal sector rotation potential from energy/tech distress to fintech/REIT recovery. Portfolio implication: overweight revenue accelerators, avoid prolonged cash burners.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 13, 2026

Across 50 Q1 2026 10-Q filings, sentiment is predominantly mixed (38/50), with 6 negative and revenue growth averaging +25% YoY in outperformers like STAAR Surgical (+120%) and Astronics (+12%), but widespread margin compression (-150 bps avg in 12/20 operating cos) and cash burn in biotechs/pharma (e.g., Semnur op ex +588% YoY). Banks/insurers show resilience with net income +50% YoY avg (e.g., Avidbank +66%, UTG +81%), while crypto ETFs suffer massive unrealized depreciation (avg -25% NAV QoQ, e.g., Canary XRP -18%). Capital allocation leans conservative with buybacks/dividends in banks (Embassy repurchased $3M shares) amid rising debt in 15 cos (avg +10% QoQ). Portfolio trend: 22/50 cos improved op cash flow YoY, signaling working capital stabilization, but 18/50 deepened losses/stockholders' deficits. Key implication: Rotate to banks/turnarounds (Snail +operating income swing), avoid high-burn biotechs/crypto; watch leverage in trusts/REITs. No major guidance changes, but B&G Foods flags covenant risks.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 12, 2026

Across 50 Q1 2026 10-Q filings, mixed sentiment prevails in 44/50 cases, reflecting revenue volatility with 18 companies posting YoY growth (avg +35%, led by Rocket Companies +167% and Venture Global +59%) but 12 showing sharp declines (avg -45%, worst VenHub -86% and Longduoduo -76%). Net losses narrowed in 22 biotechs/pharmas (avg improvement 25%) via cost cuts, though cash burn persists; financials/banks saw NII growth in 5/8 (avg +20%) amid deposit/loan expansion. Balance sheets strengthened via equity raises in 15 firms (total ~$300M+ proceeds), but 10 reported cash declines >20% QoQ signaling liquidity strains. Capital allocation favors dividends (e.g., Sound Financial +11% payout) over buybacks, with no major M&A but ongoing projects like Venture Global's LNG. Portfolio trend: Margin resilience in growth names (avg +150bps gross margins) vs compression in decliners (-200bps avg), implying rotation to outperformers like Ducommun (+216% op income) amid sector dispersion.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 11, 2026

Across 50 Q1 2026 10-Q and 10-K filings, results are predominantly mixed, with 28/50 companies (56%) reporting YoY revenue growth averaging +35% in outperformers like NESR (+33.5%), Gold.com (+244%), and Liquidia (from $3K to $133K), but declines in 22/50 averaging -10% in media (Townsquare -1.9%), renewables (OPAL -14%), and crypto/mining (Bitfarms -22%). Profitability trends show 24/50 achieving net income improvements or turns to profit (e.g., RingCentral from loss to $31M), but 26/50 widened losses amid rising expenses, impairments, and unrealized losses in BDCs (FS KKR net decrease $441M vs +$120M YoY). Capital allocation remains shareholder-friendly with 18/50 announcing buybacks (e.g., Western Alliance $50M, Certara $40M) and 15/50 dividends (e.g., Carlyle $28M up YoY), signaling conviction despite macro pressures. Banks shine with asset growth (e.g., Prosperity +13% QoQ to $43.6B via M&A), while biotech/pharma burns cash on R&D (avg +30% YoY). M&A activity (Prosperity, Gold.com, Constellation Calpine $20B+ equiv) and financing inflows bolster balance sheets in 20/50, but going concern doubts (EchoStar) and high debt (Apollo Debt +11% QoQ) flag risks. Portfolio implication: overweight banks/energy, underweight volatile renewables/BDCs ahead of rate cuts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 08, 2026

Across 50 Q1 2026 filings, results were predominantly mixed (45/50), with revenue growth averaging ~20% YoY in high performers like tech (Cloudflare +33.5%, CoreWeave +111.6%, Fortinet +20.1%) and healthcare (Astrana +56%, AMN +100%, Natera +38.8%), but declines in media (Saga -5.6%, Nu Skin -12.1%), REITs (NewLake -7%), and select financials (DXC -1.8%). Net income trends showed sharp improvements in outperformers (Monster +28.6%, Vistra from loss to +$1B, Yum China +5.8%) offset by widening losses elsewhere (IREN -$248M, Gran Tierra -$119M), with margin compression common (avg -50 bps in 12/50) due to rising opex/SG&A. Capital allocation leaned bullish with aggressive buybacks totaling >$3B (Fortinet $823M, Republic $317M, Yum China $218M, Vistra $372M) signaling management conviction, while 8 companies issued equity/diluted shares. Cash flows improved in 28/50 (e.g., Republic +19.7% to $1.2B), but capex surges (Ameren +48%, CoreWeave $7.7B) and impairments pressured balance sheets. Portfolio implications favor selective longs in growth tech/healthcare/energy amid broader caution on cyclicals/media; watch buyback acceleration as stabilizer.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 07, 2026

Across 50 10-Q filings dated May 7, 2026, for Q1 ending March 31, 2026, companies displayed mixed financial results with robust revenue growth in standout names (Amcor +77% YoY, GigaCloud +32% YoY, Walker & Dunlop +27% YoY, PTC +22% YoY) contrasting profitability headwinds and cash flow strains in others (Arhaus op income -61% YoY, Ares net loss swing, GigaCloud OCF to -$22M). Period-over-period trends reveal average revenue acceleration driven by acquisitions (Amcor Berry), originations (Walker), and product demand (PTC licenses +43% YoY), but margins compressed portfolio-wide due to rising expenses (Generate R&D +23% YoY), provisions (Ares $11M CECL), and amortization (Amcor +$97M YoY). Capital allocation leaned toward returns (PTC $826M buybacks reducing shares 4%, GigaCloud $12M repurchases, Arhaus $50M dividend) amid liquidity builds (Generate $369M IPO proceeds). Sector patterns highlight financials/REITs facing credit pressures (Ares equity -3.4% QoQ), tech/consumer resilience, and biotechs/biopharma cash burn (Generate net loss to $69M). Market implications favor selective longs in growth outperformers while cautioning on cash conversion risks; no major insider activity or guidance changes noted across detailed filings, with all medium risk and materiality 6-9/10.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 06, 2026

Across 50 Q1 2026 filings, mixed sentiments dominate (44/50 mixed or negative), with revenue growth averaging +15% YoY in outperformers like tech (AMD +38%, Arista +35%, Lumentum +90%) but declines in energy (Talos -8%), diagnostics (QuidelOrtho -10.5%), and utilities (Tucson Electric -7.5%); margins compressed in 28/50 companies (avg -150 bps where noted, e.g., Atkore -27% gross profit drop). Net income swung positive in turnaround stories (Taboola + from loss, JBT Marel +$45M from -$173M loss) but widened losses in biotechs (Ultragenyx -23% worse) and amid impairments (Talos $145M charge). Capital returns strong with buybacks (United Therapeutics $1.5B, Arista prior $787M but paused) and dividends (Yum +$0.04/share YoY), though cash piles shrank QoQ in 32/50 (avg -15%). Acquisitions boosted assets (Pinnacle doubled to $122B, Fresh Del Monte +11% QoQ) but integration costs pressured EPS. Portfolio trend: Tech/healthcare M&A active, financials resilient via deals; watch biotech catalysts like Polomar trials (Feb 2026). Implications: Favor tech growth names, avoid margin-squeezed industrials; sector rotation to strong cash flow generators amid capex surges.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 05, 2026

Across 50 Q1 2026 10-Q filings, sentiment is overwhelmingly mixed (46/50), with revenue growth in 35/50 companies averaging +18% YoY (outliers like Fabrinet +39%, EVgo +45%, Paymentus +30%), but offset by net income declines or widened losses in 28/50 due to expense inflation (avg +20% YoY in SG&A/R&D) and higher interest/provisions. Cash flows show volatility: operating cash up YoY in 22/50 (e.g., Duolingo +43%, Gartner +25%), but down or negative in 18/50 amid inventory/receivable builds. Capital allocation leans shareholder-friendly with buybacks in 12 companies (e.g., Gartner $535M, TopBuild via share reduction) and dividend hikes (e.g., Amalgamated +21%, Tompkins +8%), while debt reductions signal deleveraging in 10 firms. Financials exhibit NII growth (+10% avg) but rising provisions; tech/energy mixed with volume gains but derivative/opex hits. Portfolio implication: Favor high-growth outliers like Duolingo/Shopify for momentum, monitor cash burn in biotechs/loss-makers; sector rotation toward profitable industrials (AGCO, Fabrinet). No major insider patterns noted, but buyback aggression flags conviction in mature names.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 04, 2026

Across 50 Q1 2026 US SEC filings, revenue growth was resilient with 38/50 companies reporting YoY increases averaging 12.5% (range 0.7%-2600%), driven by core operations, acquisitions, and international expansion, though profitability was volatile with 25 firms seeing net income declines due to impairments, higher costs, and one-offs. Margin trends mixed: gross margins expanded in 22 cases (avg +500bps in food/tech) but compressed in energy/insurance (avg -200bps). Capital allocation robust with $15B+ in dividends/buybacks (e.g., Progressive $8B dividend, Berkshire $236M buybacks), signaling management confidence amid $20B+ M&A spend. Biotech/pharma (12 firms) narrowed losses 40% avg on rev ramps, energy/oil (5 firms) faced input cost pressures (-30% NI avg), financials (8 firms) grew NII 8% avg with stable provisions. No major guidance changes noted, but forward capex/dividend hikes flag H2 catalysts; mixed sentiment (46/50) implies sector rotation opportunities in improving biotechs vs pressured cyclicals. Portfolio implication: overweight growth biotechs/financials, underweight energy amid OPEX inflation.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 01, 2026

Across 50 Q1 2026 10-Q filings, companies exhibited resilient revenue growth in approximately 70% of cases (avg +12% YoY where positive), led by tech (Teradyne +87%), financials (BNY Mellon +13%), and industrials (SPX +17.5%), but profitability was mixed with 40% reporting net income declines due to M&A integration costs, impairments, and one-offs like First Merchants' $30M mortgage loss. Robust capital allocation prevailed, with 35+ firms executing buybacks (e.g., Verizon $2.5B, Ryan $40M) and dividends (e.g., BNY $0.53/share), signaling management conviction amid asset expansion from acquisitions in 20+ companies (totaling billions, e.g., SPX $440M, Boston Sci $588M). Margin compression affected 25% of filers (avg -150bps, e.g., Smurfit -196bps gross), while operating cash flows improved YoY in 60% (e.g., Cboe doubled). Financials and tech outperformed consumer/industrials, implying bullish rotation to growth sectors; however, real estate showed impairment risks (SL Green $35M reserves). Portfolio implication: Favor acquirers with strong cash flow and returns, avoid margin squeezes; M&A wave supports consolidation plays but watch integration.

50 high priority 50 total filings